Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited
Key Takeaways
- Both drugs are dual-receptor agonists: survodutide hits GLP-1 plus glucagon; tirzepatide hits GLP-1 plus GIP
- Cross-trial weight loss: tirzepatide ~22.5% at 15 mg (SURMOUNT-1, phase 3) vs survodutide ~19% at 4.8 mg (phase 2)
- Tirzepatide is FDA-approved for obesity (Zepbound) and type 2 diabetes (Mounjaro). Survodutide is investigational
- Survodutide has a distinctive MASH liver-disease story that tirzepatide does not directly target
- Survodutide is not commercially available. FormBlends does not sell or supply survodutide
Direct answer
Survodutide and tirzepatide are both injectable dual-receptor agonists, but they differ in their second receptor target. Tirzepatide adds GIP receptor activity to GLP-1, optimized for incretin amplification and glycemic control alongside weight loss. Survodutide adds glucagon receptor activity to GLP-1, optimized for direct hepatic fat reduction and energy expenditure. Cross-trial estimates suggest tirzepatide produces somewhat more weight loss; survodutide has stronger liver-disease evidence. Tirzepatide is approved and available; survodutide is investigational.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What each drug actually does at the receptor level
- The design rationale behind each second receptor choice
- Headline efficacy numbers
- The MASH dimension
- Side-effect profile comparison
- Glycemic control and diabetes positioning
- Regulatory status and access
- Real-world considerations
- The contrary view: GIP vs glucagon debates
- FAQ
- Sources
What each drug actually does at the receptor level
Tirzepatide. A single peptide engineered as a "twincretin" that binds both GLP-1 and GIP receptors. Activates GLP-1 like semaglutide; the GIP receptor activity is well documented at the binding-affinity level. The exact functional consequence of tirzepatide's GIP receptor activity remains an active area of research; some preclinical work supports agonism, antagonism, or biased signaling at GIP receptors under different conditions. The clinical-trial endpoint result is that tirzepatide produces more weight loss than equivalent-exposure semaglutide.
Survodutide. A peptide that binds GLP-1 and glucagon receptors. GLP-1 binding is similar to other GLP-1 agonists. Glucagon receptor binding produces hepatic effects (increased fatty acid oxidation, reduced lipogenesis, increased ketogenesis) and systemic effects (increased basal metabolic rate). The receptor selectivity ratio between GLP-1 and glucagon affinity is a tunable design parameter; survodutide's specific balance was chosen during preclinical development.
Neither drug activates all three of the major incretin/glucagon family members. Retatrutide (also investigational, from Eli Lilly) is the triple agonist that hits GLP-1, GIP, and glucagon all together.
The design rationale behind each second receptor choice
The case for GIP (tirzepatide's choice). GIP is the body's second incretin, secreted from intestinal K cells in response to meals. It enhances insulin secretion via mechanisms partially overlapping with GLP-1. Adding GIP activation to GLP-1 amplifies the meal-response insulin signal, which improves glycemic control. The weight-loss enhancement (compared to GLP-1 monotherapy) is thought to come through neural circuits in the hindbrain that are not fully mapped.
The case for glucagon (survodutide's choice). Glucagon increases hepatic fatty acid oxidation, raises basal metabolic rate, and reduces hepatic fat. Stacked onto GLP-1, it adds an energy-expenditure dimension that GLP-1 alone does not produce. The risk is glycemic destabilization (glucagon raises glucose), which the GLP-1 component is intended to offset.
The design trade-off: GIP/GLP-1 is the safer-looking incretin-amplification path with more predictable glycemic effects. GLP-1/glucagon is the higher-conceptual-risk, higher-conceptual-reward path with direct hepatic action.
Headline efficacy numbers
| Drug | Trial | Duration | Mean weight loss |
|---|---|---|---|
| Tirzepatide 15 mg | SURMOUNT-1 (phase 3) | 72 weeks | ~22.5% |
| Tirzepatide 10 mg | SURMOUNT-1 (phase 3) | 72 weeks | ~19.5% |
| Tirzepatide 5 mg | SURMOUNT-1 (phase 3) | 72 weeks | ~15.0% |
| Survodutide 4.8 mg | Phase 2 obesity (le Roux 2024) | 46 weeks | ~19% |
| Survodutide 2.4 mg | Phase 2 obesity | 46 weeks | ~14% |
Direct comparison is unfair: tirzepatide's number is phase 3 at 72 weeks; survodutide's is phase 2 at 46 weeks. Phase 3 weight loss for tirzepatide ran ~17% at the 46-week mark, which is roughly comparable to survodutide's phase 2 number at the same time point.
Conservative summary: at currently comparable time points, tirzepatide and survodutide produce roughly similar weight loss. The longer time horizon may diverge them. Phase 3 survodutide data is needed for a fair comparison.
The MASH dimension
This is where survodutide differentiates.
Survodutide's phase 2 MASH trial showed substantial histological resolution and fibrosis improvement at 48 weeks. The glucagon component is thought to drive direct hepatic fat reduction beyond what would be expected from weight loss alone.
Tirzepatide's MASH evidence is less direct. SURPASS-3 and other diabetes trials showed favorable liver enzyme and fat measurements, but no biopsy-endpoint MASH trial of tirzepatide has been published at the scale of the survodutide MASH study. Lilly is conducting tirzepatide MASH trials, but the survodutide MASH story is more developed.
For a patient whose primary indication is MASH (in addition to obesity and diabetes), survodutide may eventually offer a more direct value case. For a patient whose primary indication is obesity or diabetes without significant liver disease, tirzepatide is the available option with established efficacy.
Side-effect profile comparison
| Event | Tirzepatide 15 mg (SURMOUNT-1) | Survodutide 4.8 mg (phase 2) |
|---|---|---|
| Nausea | ~31% | ~50-60% |
| Diarrhea | ~23% | ~30-40% |
| Vomiting | ~13% | ~25-30% |
| Constipation | ~17% | Variable |
| Discontinuation for AEs | ~7% | Variable; titration-dependent |
Survodutide's phase 2 showed somewhat higher GI rates than tirzepatide's. Whether this is intrinsic to the molecule or reflects the trial's titration schedule is hard to determine from phase 2 alone. Phase 3 data may show different rates with refined titration.
Specific glucagon-related safety considerations for survodutide:
- Modest mean heart rate increase (similar to other incretin-class drugs)
- Theoretical risk of hyperglycemia from glucagon agonism; not observed in phase 2 trials
- Lipid effects: mixed signal, generally improved alongside weight loss
- Hepatic safety: favorable in the MASH population specifically
Glycemic control and diabetes positioning
Tirzepatide is the established standard. The SURPASS-1 through SURPASS-5 trial program demonstrated HbA1c reductions of 1.5-2.5 percentage points in type 2 diabetes, with most patients reaching glycemic targets. Tirzepatide is FDA-approved for diabetes (Mounjaro brand) and is increasingly prescribed in clinical practice.
Survodutide is in phase 3 diabetes development. Phase 2 results showed HbA1c reductions consistent with effective dual agonism. The glucagon component, which acutely raises glucose, did not produce net hyperglycemia, presumably because the GLP-1 component offsets it.
For diabetes today, tirzepatide is the option. Survodutide is the option that may be available in 2027-2028.
Regulatory status and access
| Attribute | Tirzepatide | Survodutide |
|---|---|---|
| FDA approval status | Approved (Zepbound, Mounjaro) | Investigational, phase 3 |
| Available now | Yes | No, except in trials |
| Telehealth availability | Common | Not available |
| Insurance coverage | Variable; some plans cover | Not applicable yet |
| Compounded version | Limited post-shortage | None legitimate |
From a current-patient standpoint, tirzepatide is the option that exists. Survodutide is a future option.
Real-world considerations
Cost. Tirzepatide list price is roughly $1,000-$1,400 per month. Manufacturer savings card reduces this for eligible patients. Lilly Direct cash-pay options have expanded access. Survodutide's price at launch is unknown but likely in a similar range.
Cardiovascular evidence. Semaglutide has SELECT trial data showing CV benefit. Tirzepatide has SURPASS-CVOT data establishing CV safety. Survodutide CV outcomes will accumulate over the SYNCHRONIZE-3 trial timeline.
Long-term durability. SURMOUNT-4 showed weight regain after stopping tirzepatide, with the implication that chronic therapy is necessary. Survodutide will face the same chronic-treatment requirement; no obesity drug has yet demonstrated post-cessation durability.
Specialty vs primary care. Tirzepatide is increasingly prescribed in primary care. Survodutide's MASH positioning may push it more toward hepatology and endocrinology specialty practices, depending on labeling.
The contrary view: GIP vs glucagon debates
The GIP versus glucagon debate among researchers is more philosophical than the trial-data picture suggests.
The case against GIP. Some early work suggested GIP receptor agonism could promote obesity rather than prevent it; tirzepatide's clinical success contradicted this. The mechanism of tirzepatide's GIP component remains debated.
The case against glucagon. Sustained glucagon agonism could theoretically destabilize glycemia and increase cardiovascular risk via lipid effects. Survodutide phase 2 has not shown these signals, but long-term and broader-population data are needed.
The case for both being valid. Both approaches have produced substantial weight loss with acceptable safety in trials. Neither has revealed a fatal flaw. The therapeutic competition between GIP/GLP-1 and GLP-1/glucagon paradigms may resolve through patient phenotyping, with different drugs suiting different patients.
Decision framework
If you need treatment now and qualify for either approved drug: tirzepatide is the available option. Survodutide is not.
If you have MASH plus obesity: survodutide may eventually offer a stronger combined value proposition. For now, weight loss through any available means produces liver benefit; resmetirom is the approved MASH option.
If you've tried tirzepatide and want a different mechanism: when survodutide launches, it would offer a distinct dual-agonist option. In the meantime, semaglutide (different molecule, GLP-1 only) is the available alternative.
If you're researching the drug landscape: retatrutide (triple agonist), survodutide (GLP-1/glucagon), tirzepatide (GLP-1/GIP), CagriSema (GLP-1 + amylin combo), and semaglutide (GLP-1) span the major mechanism categories. Each has trade-offs in efficacy, side-effect profile, and indication breadth.
Compounded medication note for this topic
For Survodutide vs Tirzepatide: Different Second Receptors, Different Stories, keep the pharmacy distinction clear: when compounded semaglutide or tirzepatide is prescribed, it is prepared for an individual patient by a licensed 503A compounding pharmacy. Compounded preparations are not FDA-approved drug products and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.
The practical question is not whether a compounded medication is a brand substitute. It is whether the prescription, pharmacy label, concentration, follow-up plan, and adverse-event support are clear enough for your specific medical history.
FAQ
Is survodutide a triple agonist? No. It is a dual agonist of GLP-1 and glucagon. Retatrutide is the triple agonist (GLP-1 + GIP + glucagon).
Is tirzepatide a triple agonist? No. It is a dual agonist of GLP-1 and GIP.
Which one is more effective? Tirzepatide has phase 3 data showing ~22.5% at 15 mg. Survodutide phase 2 showed ~19% at the highest dose. Phase 3 survodutide data will inform a fair comparison.
Is survodutide available now? No, except in clinical trials.
Can I take both? No. Combining incretin-class drugs has no evidence base and predictably stacks side effects.
Will survodutide replace tirzepatide? Unlikely. They will probably coexist as options targeting different patient phenotypes.
Which has more cardiovascular evidence? Tirzepatide has SURPASS-CVOT. Survodutide CV evidence is still accruing.
Which has better diabetes evidence? Tirzepatide, by a wide margin (SURPASS-1 through -5 plus real-world data).
Which has better MASH evidence? Survodutide, based on the phase 2 trial. Tirzepatide MASH-specific trials are smaller and earlier stage.
What about side effects? Both produce GI-dominant adverse events. Phase 2 survodutide showed higher rates than tirzepatide; phase 3 with refined titration may narrow that gap.
Is one cheaper than the other? Tirzepatide list price ~$1,000-$1,400. Survodutide price unknown until launch.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
- le Roux CW et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity (phase 2). Lancet. 2024.
- Sanyal AJ et al. Survodutide in MASH and Liver Fibrosis (phase 2). New England Journal of Medicine. 2024.
- Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2). NEJM. 2021.
- Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes (SELECT). NEJM. 2023.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
- Boehringer Ingelheim. SYNCHRONIZE Phase 3 Program Disclosures. 2024-2025.
- American Diabetes Association. Standards of Care in Diabetes - 2025. Diabetes Care. 2025.
- Endocrine Society. Pharmacological Management of Obesity Clinical Practice Guideline. 2024 update.
Footer disclaimers
Platform Disclaimer. FormBlends is a telehealth platform connecting patients with independent licensed clinicians. We do not manufacture or supply survodutide and do not sell investigational medications. Clinical decisions are made by treating prescribers.
Investigational Drug Notice. Survodutide is investigational and not FDA-approved as of May 2026. Tirzepatide (Zepbound, Mounjaro) is FDA-approved and commercially available. Cross-trial comparisons in this article are descriptive and not a substitute for direct head-to-head clinical evidence.
Results Disclaimer. Trial outcomes referenced are group means in controlled clinical settings. Individual response varies widely. Phase 2 data is preliminary; phase 3 results may differ in magnitude.
Trademark Notice. Survodutide is a Boehringer Ingelheim and Zealand Pharma development designation. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with these companies.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →